165 related articles for article (PubMed ID: 8323381)
1. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis.
Kröger H; Risteli J; Risteli L; Penttilä I; Alhava E
Ann Rheum Dis; 1993 May; 52(5):338-42. PubMed ID: 8323381
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.
Terzolo M; Piovesan A; Osella G; Pia A; Reimondo G; Pozzi C; Raucci C; Torta M; Paccotti P; Angeli A
Calcif Tissue Int; 1993 Mar; 52(3):188-91. PubMed ID: 8481830
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of selected bone metabolism markers in rheumatoid arthritis patients.
Matuszewska A; Szechiński J
Adv Clin Exp Med; 2013; 22(2):193-202. PubMed ID: 23709375
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
[TBL] [Abstract][Full Text] [Related]
5. The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.
Szeremeta A; Jura-Półtorak A; Komosińska-Vassev K; Zoń-Giebel A; Kapołka D; Olczyk K
Scand J Rheumatol; 2017 May; 46(3):171-179. PubMed ID: 27775453
[TBL] [Abstract][Full Text] [Related]
6. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
7. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
[TBL] [Abstract][Full Text] [Related]
8. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
[TBL] [Abstract][Full Text] [Related]
9. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in bone turnover in 2-year-old Thoroughbreds.
Jackson BF; Lonnell C; Verheyen K; Wood JL; Pfeiffert DU; Price JS
Equine Vet J; 2003 Nov; 35(7):702-6. PubMed ID: 14649363
[TBL] [Abstract][Full Text] [Related]
12. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
Conti A; Sartorio A; Ferrero S; Ferrario S; Ambrosi B
J Endocrinol Invest; 1996 Feb; 19(2):127-30. PubMed ID: 8778165
[TBL] [Abstract][Full Text] [Related]
13. Type I collagen and procollagen fragments in patients with metabolic bone diseases.
Lin JS; Kao JT; Tsai KS
J Formos Med Assoc; 1996 Jul; 95(7):523-9. PubMed ID: 8840753
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
15. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
16. Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas.
Osella G; Terzolo M; Reimondo G; Piovesan A; Pia A; Termine A; Paccotti P; Angeli A
J Clin Endocrinol Metab; 1997 Oct; 82(10):3303-7. PubMed ID: 9329358
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of bone formation markers in bone metastasis of prostate cancer.
Koizumi M; Maeda H; Yoshimura K; Yamauchi T; Kawai T; Ogata E
Br J Cancer; 1997; 75(11):1601-4. PubMed ID: 9184174
[TBL] [Abstract][Full Text] [Related]
18. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level.
Charles P; Hasling C; Risteli L; Risteli J; Mosekilde L; Eriksen EF
Calcif Tissue Int; 1992 Dec; 51(6):406-11. PubMed ID: 1451006
[TBL] [Abstract][Full Text] [Related]
19. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].
Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G
Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895
[TBL] [Abstract][Full Text] [Related]
20. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
